Quoin Pharmaceuticals Inc (NASDAQ: QNRX) recently announced that it received the relevant authorisation from the Food and Drug Authority to proceed with the clinical investigations surrounding its recent drug QRX003. The compound is an investigational drug that, if successful, will make a significant advancement in developed treatments for Netherton Syndrome.
How the drug works
QRX003 is developed with patented technology that embodies a wide spectrum serine protease inhibitor that functions as a particular protein. The protein known as Letki is crucial to the human body, and if missing, the individual then experiences a vast amount of skin discharge. Michael Myers, the company’s CEO, stated that it was thrilled to issue an update of its clinical trials and receive the relevant authorisations. Myers further stated that the authorisation is a big deal for the company and any affected individuals.
The compound creates a normalised form of skin shedding and develops a firmer skin barrier. Individuals recruited in the treatment process are instructed to use the substance at least once a day. Quoin created the substance in the form of an ointment that assists in controlling some of the side effects.
Complications of Netherton Syndrome
The Netherton Syndrome is a type of ichthyosis that is an uncommon hereditary disorder that is developed as a result of the Spink5 gene mutation. Its mutation thus leads to serious skin deficiency and illnesses, including the shedding of skin.
Other complications that the mutation causes include asthma, eczema and others. Presently, there are no developed cures and treatments for the disorder. There are a few cases where patients share their experiences about the illness and how it impacted their lives. This new therapy could help such patients as it will meet their needs in a field with few treatment options.
The company is developing organisations that bear the mission to create and commercialise therapeutic products that target orphan illnesses. Orphan illnesses are the type of illnesses that is not encompassed by the pharmaceutical industry because of the sense behind making it a consideration for treatment or preventive measures.
During the announcement, Myers declared that the company intended to ensure that it assists patients suffering from orphan illnesses and their effects.
